Leo Pharma files for marketing approval of tralokinumab in Japan

Leo Pharma has filed an application for marketing authorization of tralokinumab, the company’s treatment for patients with moderate-to-severe atopic eczema, in Japan, the company announces in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app